“In terms of outbound deals in pharma, with the top 10-15 players, certainly we are seeing an increase in appetite,” said Subhakanta Bal, managing director and head of healthcare and consumer (India) at Rothschild & Co. “You could say that it is an evolution for the Indian pharma sector, where larger companies are increasingly looking at doing outbound deals.”
Overseas acquisitions: Indian drugmakers shop for deals abroad as they move away from generics
Date:
More like thisRelated
India’s thali cost rises as onion, oil and LPG prices bite, Crisil report shows
The cost of preparing a home-cooked meal rose further...
Indian households, other APAC regions highly vulnerable to El Nino-driven price shocks: S&P
New Delhi: Asia-Pacific economies, like India, Vietnam, Indonesia and...
RBI gives banks relief on priority sector lending, proposes Basel rule changes
The Reserve Bank of India (RBI) has tweaked its...
What India’s headline FDI won’t tell you and where we need to go
Foreign Direct Investment (FDI) equity inflows into India increased...